Skip to main content
Premium Trial:

Request an Annual Quote

Oxford Molecular and Oxford GlycoSciences Pen Research Agreement

Premium

OXFORD--Oxford Molecular Group announced it reached an agreement jointly with its associate companies, Cambridge Combinatorial and Cambridge Drug Discovery, to provide research services and consulting in drug design, combinatorial chemistry, and high-throughput screening to Oxford GlycoScience. The research program will initially target the design and synthesis of inhibitors of carbohydrate-processing enzymes. Oxford Molecular will use its software and discovery expertise to design multiple novel combinatorial libraries, which Cambridge Combinatorial will synthesize for screening by Cambridge Drug Discovery to identify potential drugs. Oxford Molecular and Cambridge Combinatorial have also agreed to provide consultancy services in information technology and combinatorial chemistry to Oxford GlycoScience.

Filed under

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.